Header Logo

Connection

Kimberly Yonkers to Premenstrual Syndrome

Back to Details
This is a "connection" page, showing publications Kimberly Yonkers has written about Premenstrual Syndrome.
Kimberly Yonkers
Connection Strength
9.472
Premenstrual Syndrome
  1. Yonkers KA, Altemus M, Gilstad-Hayden K, Kornstein SG, Gueorguieva R. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?: A Randomized Controlled Trial. J Clin Psychopharmacol. 2023 Jul-Aug 01; 43(4):320-325.
    View in: PubMed
    Score: 0.787
  2. Yonkers KA, Simoni M. Evidence-Based Treatments for Premenstrual Disorders. Am J Obstet Gynecol. 2018 08; 219(2):215-216.
    View in: PubMed
    Score: 0.553
  3. Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018 01; 218(1):68-74.
    View in: PubMed
    Score: 0.520
  4. Yonkers KA, Cameron B, Gueorguieva R, Altemus M, Kornstein SG. The Influence of Cyclic Hormonal Contraception on Expression of Premenstrual Syndrome. J Womens Health (Larchmt). 2017 Apr; 26(4):321-328.
    View in: PubMed
    Score: 0.501
  5. Hartlage SA, Breaux CA, Yonkers KA. Addressing concerns about the inclusion of premenstrual dysphoric disorder in DSM-5. J Clin Psychiatry. 2014 Jan; 75(1):70-6.
    View in: PubMed
    Score: 0.411
  6. Yonkers KA, Pearlstein TB, Gotman N. A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome. J Clin Psychopharmacol. 2013 Oct; 33(5):614-20.
    View in: PubMed
    Score: 0.403
  7. Epperson CN, Steiner M, Hartlage SA, Eriksson E, Schmidt PJ, Jones I, Yonkers KA. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry. 2012 May; 169(5):465-75.
    View in: PubMed
    Score: 0.366
  8. Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets. Arch Gen Psychiatry. 2012 Mar; 69(3):300-5.
    View in: PubMed
    Score: 0.361
  9. Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008 Apr 05; 371(9619):1200-10.
    View in: PubMed
    Score: 0.276
  10. Wallenstein GV, Blaisdell-Gross B, Gajria K, Guo A, Hagan M, Kornstein SG, Yonkers KA. Development and validation of the Premenstrual Symptoms Impact Survey (PMSIS): a disease-specific quality of life assessment tool. J Womens Health (Larchmt). 2008 Apr; 17(3):439-50.
    View in: PubMed
    Score: 0.276
  11. Borenstein JE, Dean BB, Leifke E, Korner P, Yonkers KA. Differences in symptom scores and health outcomes in premenstrual syndrome. J Womens Health (Larchmt). 2007 Oct; 16(8):1139-44.
    View in: PubMed
    Score: 0.266
  12. Halbreich U, Backstrom T, Eriksson E, O'brien S, Calil H, Ceskova E, Dennerstein L, Douki S, Freeman E, Genazzani A, Heuser I, Kadri N, Rapkin A, Steiner M, Wittchen HU, Yonkers K. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol. 2007 Mar; 23(3):123-30.
    View in: PubMed
    Score: 0.256
  13. Dean BB, Borenstein JE, Knight K, Yonkers K. Evaluating the criteria used for identification of PMS. J Womens Health (Larchmt). 2006 Jun; 15(5):546-55.
    View in: PubMed
    Score: 0.243
  14. Yonkers KA, Holthausen GA, Poschman K, Howell HB. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol. 2006 Apr; 26(2):198-202.
    View in: PubMed
    Score: 0.240
  15. Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C, Roberts DL, Yonkers K. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt). 2006 Jan-Feb; 15(1):57-69.
    View in: PubMed
    Score: 0.236
  16. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005 Dec; 72(6):414-21.
    View in: PubMed
    Score: 0.233
  17. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005 Sep; 106(3):492-501.
    View in: PubMed
    Score: 0.230
  18. Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord. 2005 Apr; 85(3):317-21.
    View in: PubMed
    Score: 0.224
  19. Yonkers KA. Management strategies for PMS/PMDD. J Fam Pract. 2004 Sep; Suppl:S15-20.
    View in: PubMed
    Score: 0.215
  20. Yonkers KA, Pearlstein T, Rosenheck RA. Premenstrual disorders: bridging research and clinical reality. Arch Womens Ment Health. 2003 Nov; 6(4):287-92.
    View in: PubMed
    Score: 0.203
  21. Borenstein JE, Dean BB, Endicott J, Wong J, Brown C, Dickerson V, Yonkers KA. Health and economic impact of the premenstrual syndrome. J Reprod Med. 2003 Jul; 48(7):515-24.
    View in: PubMed
    Score: 0.198
  22. Yonkers KA. Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes. Psychopharmacol Bull. 2003; 37 Suppl 1:135-47.
    View in: PubMed
    Score: 0.192
  23. Pearlstein T, Yonkers KA. Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. Expert Opin Pharmacother. 2002 Jul; 3(7):979-91.
    View in: PubMed
    Score: 0.185
  24. Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E, Freeman EW, Harrison WM, Haskett RF, Stout AL, Yonkers KA. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry. 2000 Feb; 61(2):101-9.
    View in: PubMed
    Score: 0.156
  25. Yonkers KA. Medical management of premenstrual dysphoric disorder. J Gend Specif Med. 1999 May-Jun; 2(3):55-60.
    View in: PubMed
    Score: 0.148
  26. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T, Severino S, Stout A, Stone A, Harrison W. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA. 1997 Sep 24; 278(12):983-8.
    View in: PubMed
    Score: 0.133
  27. Yonkers KA. Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? J Clin Psychiatry. 1997; 58 Suppl 3:62-7; discussion 68-9.
    View in: PubMed
    Score: 0.126
  28. Yonkers KA, Clark RH, Trivedi MH. The psychopharmacological treatment of nonmajor mood disorders. Mod Probl Pharmacopsychiatry. 1997; 25:146-66.
    View in: PubMed
    Score: 0.126
  29. Yonkers KA. Antidepressants in the treatment of premenstrual dysphoric disorder. J Clin Psychiatry. 1997; 58 Suppl 14:4-10; discussion 11-3.
    View in: PubMed
    Score: 0.126
  30. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry. 1997; 58 Suppl 15:19-25.
    View in: PubMed
    Score: 0.126
  31. Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ. Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol. 1996 Feb; 16(1):3-8.
    View in: PubMed
    Score: 0.119
  32. Yonkers KA, Halbreich U, Freeman E, Brown C, Pearlstein T. Sertraline in the treatment of premenstrual dysphoric disorder. Psychopharmacol Bull. 1996; 32(1):41-6.
    View in: PubMed
    Score: 0.118
  33. Severino SK, Yonkers KA. A literature review of psychotic symptoms associated with the premenstruum. Psychosomatics. 1993 Jul-Aug; 34(4):299-306.
    View in: PubMed
    Score: 0.099
  34. Nevatte T, O'Brien PM, B?ckstr?m T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman EW, Halbreich U, Ismail K, Panay N, Pearlstein T, Rapkin A, Reid R, Rubinow D, Schmidt P, Steiner M, Studd J, Sundstr?m-Poromaa I, Yonkers K. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health. 2013 Aug; 16(4):279-91.
    View in: PubMed
    Score: 0.098
  35. Yonkers KA, White K. Premenstrual exacerbation of depression: one process or two? J Clin Psychiatry. 1992 Aug; 53(8):289-92.
    View in: PubMed
    Score: 0.093
  36. Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009; 17(2):120-37.
    View in: PubMed
    Score: 0.073
  37. Borenstein JE, Dean BB, Yonkers KA, Endicott J. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol. 2007 May; 109(5):1068-75.
    View in: PubMed
    Score: 0.065
  38. Halbreich U, O'Brien PM, Eriksson E, B?ckstr?m T, Yonkers KA, Freeman EW. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? CNS Drugs. 2006; 20(7):523-47.
    View in: PubMed
    Score: 0.059
  39. Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord. 2005 Apr; 85(3):275-82.
    View in: PubMed
    Score: 0.056
  40. Perkonigg A, Yonkers KA, Pfister H, Lieb R, Wittchen HU. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry. 2004 Oct; 65(10):1314-22.
    View in: PubMed
    Score: 0.054
  41. Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med. 2004 Sep-Oct; 66(5):707-13.
    View in: PubMed
    Score: 0.054
  42. Yonkers KA. Special issues related to the treatment of depression in women. J Clin Psychiatry. 2003; 64 Suppl 18:8-13.
    View in: PubMed
    Score: 0.048
  43. Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2002 Dec; 100(6):1219-29.
    View in: PubMed
    Score: 0.048
  44. Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2001 Nov; 98(5 Pt 1):737-44.
    View in: PubMed
    Score: 0.044
  45. Gurguis GN, Yonkers KA, Phan SP, Blakeley JE, Williams A, Rush AJ. Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet alpha 2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity. Biol Psychiatry. 1998 Oct 01; 44(7):600-9.
    View in: PubMed
    Score: 0.036
  46. Gurguis GN, Yonkers KA, Blakeley JE, Phan SP, Williams A, Rush AJ. Adrenergic receptors in premenstrual dysphoric disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of luteal phase symptom severity. Psychiatry Res. 1998 Jun 02; 79(1):31-42.
    View in: PubMed
    Score: 0.035
  47. Halbreich U, Petty F, Yonkers K, Kramer GL, Rush AJ, Bibi KW. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry. 1996 May; 153(5):718-20.
    View in: PubMed
    Score: 0.030
  48. Yonkers KA, Chantilis SJ. Recognition of depression in obstetric/gynecology practices. Am J Obstet Gynecol. 1995 Aug; 173(2):632-8.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.